[{"from": "human", "value": "Could you give me a brief overview of this molecule? [C][C][=C][Branch2][Ring2][=Branch2][C][=C][C][=C][Ring1][=Branch1][C][=N][C][=C][C][=Branch1][=N][=C][C][=Branch1][#Branch1][=C][Ring1][=Branch1][O][Ring1][=Branch2][C][#N][C][N][C][C][C@H1][Branch1][Ring2][C][Ring1][Branch1][C][=Branch1][C][=O][O][C][=C][Branch2][Ring2][Branch1][C][=Branch1][=Branch1][=C][C][=C][Ring1][=Branch1][N][C][=N][C][=C][C][=C][C][=Branch1][Branch2][=C][N][=C][Ring1][=Branch1][Ring1][#Branch2][C][N][C][C][C@H1][Branch1][Ring2][C][Ring1][Branch1][O][C]"}, {"from": "gpt", "value": "The molecule is an orally available, small molecule inhibitor of the immunosuppressive ligand, programmed cell death-1 ligand 1 (PD-L1; cluster of differentiation 274; CD274) with potential immune checkpoint inhibitory and antineoplastic activities. Upon administration, PD-L1 inhibitor INCB086550 specifically targets PD-L1 expressed on tumor cells preventing the binding and subsequent activation of its receptor, programmed cell death 1 (PD-1; PDCD1; CD279; programmed death-1). This reverses T-cell inactivation caused by PD-L1/PD-1 signaling, increases T-cell expansion and enhances the cytotoxic T-lymphocyte (CTL)-mediated anti-tumor immune response against PD-L1-expressing tumor cells. PD-L1, a transmembrane protein expressed on activated T-cells, is overexpressed in some cancer types and plays a significant role in immune evasion by tumor cells."}]